Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Tomlinson

Showing results (1-10 of 304) with videos related to

Pageof 31
Sort By:
Heart (British Cardiac Society)|August 31, 2010
Raising high-density lipoprotein: for better or worse?Brian Tomlinson
Current Opinion in Investigational Drugs (London, England : 2000)|November 8, 2006
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factorBrian Tomlinson
Current Opinion in Investigational Drugs (London, England : 2000)|November 30, 2005
Febuxostat (Teijin/Ipsen/TAP)Brian Tomlinson
The New England Journal of Medicine|December 30, 2025
Targeting APOC3 with Olezarsen in Moderate HypertriglyceridemiaBrian Tomlinson
Expert Opinion on Biological Therapy|December 13, 2024
An up-to-date review of emerging biologic therapies for hypercholesterolemiaBrian Tomlinson
Expert Opinion on Pharmacotherapy|March 5, 2026
Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemiaBrian Tomlinson
Lancet (London, England)|May 10, 2003
SARS: experience at Prince of Wales Hospital, Hong KongBrian Tomlinson, Clive Cockram
Expert Opinion on Investigational Drugs|February 27, 2009
Tesamorelin, a human growth hormone releasing factor analogueYing Wang, Brian Tomlinson
Biologics : Targets & Therapy|November 3, 2025
Antibody-Based Therapeutics for HypercholesterolemiaBrian Tomlinson, Paul Chan
Pharmacogenomics|June 11, 2013
Pharmacogenomics of lipid-lowering therapiesMiao Hu, Brian Tomlinson
Pageof 31

Showing results (1-10 of 304) with videos related to

Sort By:
Pageof 31
Heart (British Cardiac Society)|August 31, 2010
Raising high-density lipoprotein: for better or worse?Brian Tomlinson
Current Opinion in Investigational Drugs (London, England : 2000)|November 8, 2006
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factorBrian Tomlinson
Current Opinion in Investigational Drugs (London, England : 2000)|November 30, 2005
Febuxostat (Teijin/Ipsen/TAP)Brian Tomlinson
The New England Journal of Medicine|December 30, 2025
Targeting APOC3 with Olezarsen in Moderate HypertriglyceridemiaBrian Tomlinson
Expert Opinion on Biological Therapy|December 13, 2024
An up-to-date review of emerging biologic therapies for hypercholesterolemiaBrian Tomlinson
Expert Opinion on Pharmacotherapy|March 5, 2026
Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemiaBrian Tomlinson
Lancet (London, England)|May 10, 2003
SARS: experience at Prince of Wales Hospital, Hong KongBrian Tomlinson, Clive Cockram
Expert Opinion on Investigational Drugs|February 27, 2009
Tesamorelin, a human growth hormone releasing factor analogueYing Wang, Brian Tomlinson
Biologics : Targets & Therapy|November 3, 2025
Antibody-Based Therapeutics for HypercholesterolemiaBrian Tomlinson, Paul Chan
Pharmacogenomics|June 11, 2013
Pharmacogenomics of lipid-lowering therapiesMiao Hu, Brian Tomlinson
Pageof 31